Shape Pharmaceuticals' Acquisition

Shape Pharmaceuticals was acquired by TetraLogic Pharmaceuticals on April 07, 2014.

Shape Pharmaceuticals is developing SHP-141, a novel, topical HDAC inhibitor, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL). The developm…

Articles about Shape Pharmaceuticals' Acquisition: